Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Real‐life Practice Experts for HCC (RELPEC) Study Group"'
Autor:
Atsushi Hiraoka, Takashi Kumada, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Atsushi Naganuma, Hisashi Kosaka, Hiroshi Shibata, Tomoko Aoki, Takaaki Tanaka, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Yohei Koizumi, Shinichiro Nakamura, Kouji Joko, Hiroko Iijima, Masaki Kaibori, Yoichi Hiasa, Masatoshi Kudo, Real‐life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)
Publikováno v:
Cancer Medicine, Vol 12, Iss 1, Pp 325-334 (2023)
Abstract Background/Aim A comparison of therapeutic efficacy between atezolizumab plus bevacizumab (Atez/Bev) and lenvatinib treatment given as first‐line therapy for unresectable hepatocellular carcinoma (u‐HCC) in regard to progression‐free s
Externí odkaz:
https://doaj.org/article/2bbda185ed404f0a8309cd22660018ee
Autor:
Takeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, Kazuya Kariyama, Kunihiko Tsuji, Toru Ishikawa, Hidenori Toyoda, Satoshi Yasuda, Atsushi Naganuma, Toshifumi Tada, Koichi Takaguchi, Akemi Tsutsui, Ei Itobayashi, Noritomo Shimada, Hiroshi Shibata, Takaaki Tanaka, Takuya Nagano, Michitaka Imai, Shinichiro Nakamura, Kazuhiro Nouso, Hisashi Kosaka, Masaki Kaibori, Takashi Kumada, Real‐life Practice Experts for HCC (RELPEC) Study Group
Publikováno v:
Cancer Medicine, Vol 12, Iss 1, Pp 345-357 (2023)
Abstract Aims This retrospective study compared the survival between elderly and non‐elderly patients. Methods A total of 5545 treatment‐naive patients with hepatocellular carcinoma (HCC) who visited 7 different hospitals from January 2000 to Dec
Externí odkaz:
https://doaj.org/article/f81c91b804694916abe49f7211a0322c
Autor:
Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka, Masanori Atsukawa, Masashi Hirooka, Kunihiko Tsuji, Toru Ishikawa, Koichi Takaguchi, Kazuya Kariyama, Ei Itobayashi, Kazuto Tajiri, Noritomo Shimada, Hiroshi Shibata, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Shinya Fukunishi, Hideko Ohama, Kazuhito Kawata, Joji Tani, Shinichiro Nakamura, Kazuhiro Nouso, Akemi Tsutsui, Takuya Nagano, Tanaka Takaaki, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Kouji Joko, Yohei Koizumi, Yoichi Hiasa, Real-life Practice Experts for HCC (RELPEC) Study Group and the HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
Abstract We investigated the impact on survival of modified albumin–bilirubin (mALBI) grade versus Child–Pugh classification in patients with hepatocellular carcinoma (HCC) who received lenvatinib. A total of 524 patients with HCC who received le
Externí odkaz:
https://doaj.org/article/2a6790e7eddf4f60855715ed7fd73757
Autor:
Atsushi Hiraoka, Takashi Kumada, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Yohei Koizumi, Shinichiro Nakamura, Kouji Joko, Hiroko Iijima, Yoichi Hiasa, Masatoshi Kudo, Real‐life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (Hepatocellular Carcinoma Experts from 48 Clinics in Japan)
Publikováno v:
Cancer Reports, Vol 5, Iss 2, Pp n/a-n/a (2022)
Abstract Background Although atezolizumab plus bevacizumab (Atez/bev) treatment has been developed for unresectable hepatocellular carcinoma (u‐HCC), changes in hepatic function during therapy have yet to be reported. Aim This retrospective clinica
Externí odkaz:
https://doaj.org/article/87e1b88db7584ed88e2034ac036300a1
Autor:
Kazuya Kariyama, Miwa Kawanaka, Kazuhiro Nouso, Akiko Wakuta, Shohei Shiota, Akemi Kurisu, Aya Sugiyama, Tomoyuki Akita, Takashi Kumada, Junko Tanaka, the Real‐Life Practice Experts for HCC (RELPEC) Study Group
Publikováno v:
JGH Open, Vol 8, Iss 7, Pp n/a-n/a (2024)
Abstract Background and Aim We conducted a study using the Fibrosis‐3 (FIB‐3) index, which is the established age‐independent index of fibrosis in nonviral liver disease and addresses the limitations of the FIB‐4 index in older age group, to
Externí odkaz:
https://doaj.org/article/79e9a833ed924293ae0f419843422eec
Autor:
Takeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Keisuke Yokohama, Hiroki Nishikawa, Takashi Nishimura, Noritomo Shimada, Kazuhito Kawata, Hisashi Kosaka, Atsushi Naganuma, Yutaka Yata, Hideko Ohama, Hidekatsu Kuroda, Kazunari Tanaka, Takaaki Tanaka, Fujimasa Tada, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Masatoshi Kudo, Takashi Kumada, the Real‐life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)
Publikováno v:
Cancer Medicine, Vol 12, Iss 24, Pp 21680-21693 (2023)
Abstract Aim This retrospective study compared the impact of atezolizumab plus bevacizumab (Atez/Bev) and lenvatinib (LEN) on the liver function in patients with hepatocellular carcinoma. Methods We included 526 patients who received Atez/Bev and 731
Externí odkaz:
https://doaj.org/article/47d83858206f4fedb8133cae3683b6fd
Autor:
Atsushi Hiraoka, Takashi Kumada, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Yohei Koizumi, Shinichiro Nakamura, Kouji Joko, Hiroko Iijima, Yoichi Hiasa, Masatoshi Kudo, Real‐life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (Hepatocellular Carcinoma Experts from 48 Clinics in Japan)
Publikováno v:
Cancer Reports, Vol 5, Iss 2, Pp n/a-n/a (2022)
Background Although atezolizumab plus bevacizumab (Atez/bev) treatment has been developed for unresectable hepatocellular carcinoma (u‐HCC), changes in hepatic function during therapy have yet to be reported. Aim This retrospective clinical study a
Autor:
Atsushi Hiraoka, Takashi Kumada, Masanori Atsukawa, Masashi Hirooka, Kunihiko Tsuji, Toru Ishikawa, Koichi Takaguchi, Kazuya Kariyama, Ei Itobayashi, Kazuto Tajiri, Noritomo Shimada, Hiroshi Shibata, Hironori Ochi, Toshifumi Tada, Hidenori Toyoda, Kazuhiro Nouso, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Korenobu Hayama, Michitaka Imai, Kouji Joko, Yohei Koizumi, Yoichi Hiasa, Kojiro Michitaka, Masatoshi Kudo, the Real‐life Practice Experts for HCC (RELPEC) Study Group, HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 8, Iss 8, Pp 3719-3728 (2019)
Cancer Medicine, Vol 8, Iss 8, Pp 3719-3728 (2019)
Background/aim We assessed suitable factors indicating newly developed lenvatinib (LEN) treatment for unresectable hepatocellular carcinoma (u‐HCC) by investigating real‐world clinical features of patients. Materials/methods One hundred fifty two
Autor:
Atsushi Hiraoka, Takashi Kumada, Toshifumi Tada, Joji Tani, Kazuya Kariyama, Shinya Fukunishi, Masanori Atsukawa, Masashi Hirooka, Kunihiko Tsuji, Toru Ishikawa, Koichi Takaguchi, Ei Itobayashi, Kazuto Tajiri, Noritomo Shimada, Hiroshi Shibata, Hironori Ochi, Kazuhito Kawata, Satoshi Yasuda, Hidenori Toyoda, Tomoko Aoki, Takaaki Tanaka, Hideko Ohama, Kazuhiro Nouso, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Taeang Arai, Tomomi Okubo, Michitaka Imai, Yohei Koizumi, Shinichiro Nakamura, Koji Joko, Yoichi Hiasa, Masatoshi Kudo, The Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
Scientific Reports
Scientific Reports
Background/Aim: Hepatocellular carcinoma patients (HCC) related with non-alcoholic steatohepatitis (NASH) has been recently reported to be not responsive to immune-checkpoint inhibitor treatment (ICI). This study aimed to evaluate therapeutic efficac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eca55587817c3cda0ccc051235e5c1d5
https://doi.org/10.21203/rs.3.rs-395059/v1
https://doi.org/10.21203/rs.3.rs-395059/v1
Autor:
Kazuya Kariyama, Kazuhiro Nouso, Hidenori Toyoda, Toshifumi Tada, Atsushi Hiraoka, Kunihiko Tsuji, Ei Itobayashi, Toru Ishikawa, Akiko Wakuta, Ayano Oonishi, Takashi Kumada, Masatoshi Kudo, on behalf of the Real-Life Practice Experts for HCC (RELPEC) Study Group, HCC fourtyeight Group
Publikováno v:
Cancers
Volume 11
Issue 2
Cancers, Vol 11, Iss 2, p 203 (2019)
Volume 11
Issue 2
Cancers, Vol 11, Iss 2, p 203 (2019)
Background: Most integrated scores for predicting the prognosis of patients with hepatocellular carcinoma (HCC) comprise tumor progression factors and liver function variables. The FIB4 index is an indicator of hepatic fibrosis calculated on the basi